Granted Patent
B2
US 12,319,913 · App. 17/534,520 · Granted Jun 3, 2025
5-halouracil-modified microRNAs and their use in the treatment of cancer
Inventors:
Jingfang Ju (East Setauket, NY); Andrew Fesler (Sound Beach, NY); Younghwa Song (Port Jefferson Station, NY); Jun Chung (Setauket, NY)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions comprising the modified nucleic acid compositions, and methods for treating cancers using the same.
Claims (5)
1. A double-stranded modified microRNA nucleic acid composition for treating a triple negative breast cancer comprising a modified nucleotide sequence having uracil nucleic acids, wherein all the uracil nucleic acids including the seed region of the modified microRNA nucleotide sequence are 5-fluorouracils which is complementary to a portion of a MDC1 3′UTR nucleotide sequence or to a portion of a SUZ12 3′ UTR nucleotide sequence, to increase the potency of the modified microRNA nucleic acid composition in inhibiting cancer progression compared to 5-fluorouracil alone or a combination of 5-fluorouracil and a native microRNA, and the modified microRNA nucleotide sequence is CGACGGCAU F AU F ACACU F ACAGU F G [SEQ ID NO. 32] and wherein the modified microRNA nucleic acid binds to the complementary portion of the MDC1 3′UTR nucleotide sequence set forth in SEQ ID NO: 33 or the complementary portion of the SUZ12 3′ UTR nucleotide sequence set forth in SEQ ID NO 34.
2. The composition of claim 1 , wherein said modified microRNA nucleotide sequence comprises a microRNA nucleotide sequence of miR-489 as set forth in SEQ ID NO: 31.
3. The composition of claim 2 , wherein the modified microRNA nucleic acid binds to a complementary portion of the MDC1 3′UTR nucleotide sequence set forth in SEQ ID NO: 33.
4. The composition of claim 2 , wherein the modified microRNA nucleic acid binds to a complementary portion of the SUZ12 3′ UTR nucleotide sequence set forth in SEQ ID NO: 34.
5. A pharmaceutical composition comprising the modified microRNA nucleic acid composition of claim 1 .
Continuity (3)
References Cited (397)
US 6974672B2
· Powers et al.
· 2005
[cited by applicant]
US 7993863B2
· Zetter et al.
· 2011
[cited by applicant]
US 8071559B2
· Hannon et al.
· 2011
[cited by applicant]
US 8258111B2
· Shen et al.
· 2012
[cited by applicant]
US 8318690B2
· Collard et al.
· 2012
[cited by applicant]
US 8399248B2
· Cleary et al.
· 2013
[cited by applicant]
US 8748098B2
· Hernando et al.
· 2014
[cited by applicant]
US 8822144B2
· Chajut et al.
· 2014
[cited by applicant]
US 8846631B2
· Marcusson et al.
· 2014
[cited by applicant]
US 8927207B2
· Ju et al.
· 2015
[cited by applicant]
US 8980854B2
· Boll et al.
· 2015
[cited by applicant]
US 8993533B2
· Collard et al.
· 2015
[cited by applicant]
US 9044506B2
· Rosin-Arbesfeld et al.
· 2015
[cited by applicant]
US 9084770B2
· Tachas et al.
· 2015
[cited by applicant]
US 9133455B2
· Elmén et al.
· 2015
[cited by applicant]
US 9157080B2
· Pass et al.
· 2015
[cited by applicant]
US 9238838B2
· Markel et al.
· 2016
[cited by applicant]
US 9243296B2
· Chajut et al.
· 2016
[cited by applicant]
US 9255267B2
· Mendell et al.
· 2016
[cited by applicant]
US 9333218B2
· Wang et al.
· 2016
[cited by applicant]
US 9487781B2
· Yerushalmi
· 2016
[cited by applicant]
US 9492414B2
· Tavazoie et al.
· 2016
[cited by applicant]
US 9499869B2
· Cohn et al.
· 2016
[cited by applicant]
US 9528110B2
· Collard et al.
· 2016
[cited by applicant]
US 9546366B2
· Gupte
· 2017
[cited by applicant]
US 9574239B2
· Croce
· 2017
[cited by applicant]
US 9611477B2
· Collard et al.
· 2017
[cited by applicant]
US 9611478B2
· Kelnar et al.
· 2017
[cited by applicant]
US 9642821B2
· Chowdhury
· 2017
[cited by applicant]
US 9663785B2
· Collard et al.
· 2017
[cited by applicant]
US 9677074B2
· Collard et al.
· 2017
[cited by applicant]
US 9682095B2
· Berezikov et al.
· 2017
[cited by applicant]
US 9687467B2
· Zetter et al.
· 2017
[cited by applicant]
US 9688985B2
· Bhat et al.
· 2017
[cited by applicant]
US 9714423B2
· Collard et al.
· 2017
[cited by applicant]
US 9725756B2
· Collard et al.
· 2017
[cited by applicant]
US 9732339B2
· Collard et al.
· 2017
[cited by applicant]
US 9758785B2
· Anderson et al.
· 2017
[cited by applicant]
US 9873916B2
· Myomoto et al.
· 2018
[cited by applicant]
US 9878050B2
· Rana
· 2018
[cited by applicant]
US 9879264B2
· Collard et al.
· 2018
[cited by applicant]
US 9895414B2
· Cowin et al.
· 2018
[cited by applicant]
US 9902958B2
· Collard et al.
· 2018
[cited by applicant]
US 9902959B2
· Collard et al.
· 2018
[cited by applicant]
US 9902995B2
· Collard et al.
· 2018
[cited by applicant]
US 9920322B2
· Collard et al.
· 2018
[cited by applicant]
US 9920369B2
· Collard et al.
· 2018
[cited by applicant]
US 9932585B2
· Bassell et al.
· 2018
[cited by applicant]
US 9970007B2
· Chau
· 2018
[cited by applicant]
US 9988690B2
· Hoshen et al.
· 2018
[cited by applicant]
US 9993567B2
· Feinstein
· 2018
[cited by applicant]
US 20050261217A1
· Dobie et al.
· 2005
[cited by applicant]
US 20050261218A1
· Esau et al.
· 2005
[cited by applicant]
US 20070259349A1
· Bentwich et al.
· 2007
[cited by applicant]
US 20070259350A1
· Bentwich et al.
· 2007
[cited by applicant]
US 20070259352A1
· Bentwich et al.
· 2007
[cited by applicant]
US 20080076674A1
· Litman et al.
· 2008
[cited by applicant]
US 20090136957A1
· Ivanovska et al.
· 2009
[cited by applicant]
US 20090137504A1
· Echwald et al.
· 2009
[cited by applicant]
US 20090163435A1
· Bader et al.
· 2009
[cited by applicant]
US 20090209621A1
· Mendell et al.
· 2009
[cited by applicant]
US 20090253780A1
· Takeshita et al.
· 2009
[cited by applicant]
US 20100113284A1
· Aristarkhov et al.
· 2010
[cited by applicant]
US 20100311815A1
· Chinnaiyan et al.
· 2010
[cited by applicant]
US 20110071215A1
· Pass et al.
· 2011
[cited by applicant]
US 20110118337A1
· Chau et al.
· 2011
[cited by applicant]
US 20110166200A1
· Zhang et al.
· 2011
[cited by applicant]
US 20110172293A1
· Fish et al.
· 2011
[cited by applicant]
US 20110269814A1
· Manoharan et al.
· 2011
[cited by applicant]
US 20120087992A1
· Ju et al.
· 2012
[cited by applicant]
US 20120184603A1
· Litman et al.
· 2012
[cited by applicant]
US 20120264131A1
· Goel et al.
· 2012
[cited by applicant]
US 20130085077A1
· Croce et al.
· 2013
[cited by applicant]
US 20130123138A1
· Pass et al.
· 2013
[cited by applicant]
US 20140363469A1
· Meyers et al.
· 2014
[cited by applicant]
US 20150087607A1
· Marcusson et al.
· 2015
[cited by applicant]
US 20150167007A1
· Collard et al.
· 2015
[cited by applicant]
US 20160312301A1
· Lee et al.
· 2016
[cited by applicant]
US 20170015999A1
· Yerushalmi
· 2017
[cited by applicant]
US 20170081666A1
· Yao et al.
· 2017
[cited by applicant]
US 20180207191A1
· Lancaster et al.
· 2018
[cited by applicant]
US 20180221393A1
· Peled et al.
· 2018
[cited by applicant]
US 20190112665A1
· Hoshen et al.
· 2019
[cited by applicant]
US 20200140859A1
· Pandolfi et al.
· 2020
[cited by applicant]
US 20220145304A1
· Ju et al.
· 2022
[cited by applicant]
CN 103476931A
· 2013
[cited by applicant]
CN 110290794A
· 2019
[cited by applicant]
CN 112739381A
· 2021
[cited by applicant]
CN 112996568A
· 2021
[cited by applicant]
CN 113573736A
· 2021
[cited by applicant]
EP 2090665A2
· 2009
[cited by applicant]
EP 2152722A2
· 2010
[cited by applicant]
EP 2370582A2
· 2011
[cited by applicant]
EP 2296669B1
· 2012
[cited by applicant]
EP 2471956A1
· 2012
[cited by applicant]
EP 1978986B1
· 2013
[cited by applicant]
EP 2183393B1
· 2014
[cited by applicant]
EP 3159410A2
· 2017
[cited by applicant]
EP 3187191A1
· 2017
[cited by applicant]
EP 2569432B1
· 2017
[cited by applicant]
EP 2113567B1
· 2019
[cited by applicant]
EP 2370580B1
· 2019
[cited by applicant]
EP 2963116B1
· 2020
[cited by applicant]
EP 3736022A2
· 2020
[cited by applicant]
EP 3800256A1
· 2021
[cited by applicant]
JP 2008519606A
· 2008
[cited by applicant]
JP 2009505639A
· 2009
[cited by applicant]
JP 2009507918A
· 2009
[cited by applicant]
JP 2009521952A
· 2009
[cited by applicant]
JP 2009543552A
· 2009
[cited by applicant]
JP 2010504349A
· 2010
[cited by applicant]
JP 2010504350A
· 2010
[cited by applicant]
JP 2010510964A
· 2010
[cited by applicant]
JP 2010529966A
· 2010
[cited by applicant]
JP 2011519951A
· 2011
[cited by applicant]
JP 2012532123A
· 2012
[cited by applicant]
JP 5198430B2
· 2013
[cited by applicant]
JP 2013166766A
· 2013
[cited by applicant]
JP 2014502606A
· 2014
[cited by applicant]
JP 5535076B2
· 2014
[cited by applicant]
JP 5592251B2
· 2014
[cited by applicant]
JP 2014221786A
· 2014
[cited by applicant]
JP 2015504847A
· 2015
[cited by applicant]
JP 2015518710A
· 2015
[cited by applicant]
JP 2015518711A
· 2015
[cited by applicant]
JP 2015518712A
· 2015
[cited by applicant]
JP 2015518713A
· 2015
[cited by applicant]
JP 2015518714A
· 2015
[cited by applicant]
JP 2015519057A
· 2015
[cited by applicant]
JP 2015523853A
· 2015
[cited by applicant]
JP 2015523854A
· 2015
[cited by applicant]
JP 2015523855A
· 2015
[cited by applicant]
JP 5841024B2
· 2016
[cited by applicant]
JP 2016521556A
· 2016
[cited by applicant]
JP 5971948B2
· 2016
[cited by applicant]
JP 6033527B2
· 2016
[cited by applicant]
JP 6081798B2
· 2017
[cited by applicant]
JP 6099868B2
· 2017
[cited by applicant]
JP 2017511694A
· 2017
[cited by applicant]
JP 2017171641A
· 2017
[cited by applicant]
JP 2019512014A
· 2019
[cited by applicant]
JP 2019533697A
· 2019
[cited by applicant]
JP 6704883B2
· 2020
[cited by applicant]
JP 6738841B2
· 2020
[cited by applicant]
JP 202131420A
· 2021
[cited by applicant]
JP 202131421A
· 2021
[cited by applicant]
JP 7130639B2
· 2022
[cited by applicant]
KR 101343616B1
· 2013
[cited by applicant]
KR 1020150142122A
· 2015
[cited by applicant]
KR 101596166A
· 2016
[cited by applicant]
KR 1020160029053A
· 2016
[cited by applicant]
KR 101612356A
· 2016
[cited by applicant]
KR 20160113321A
· 2016
[cited by applicant]
KR 101838308B1
· 2018
[cited by applicant]
KR 101853508B1
· 2018
[cited by applicant]
KR 101857090B1
· 2018
[cited by applicant]
KR 1020200104249A
· 2020
[cited by applicant]
KR 20210139237A
· 2021
[cited by applicant]
WO 9641809A1
· 1996
[cited by applicant]
WO 03029459A2
· 2003
[cited by applicant]
WO 2006128245A1
· 2006
[cited by applicant]
WO 2006133022A9
· 2007
[cited by applicant]
WO 2007016548A2
· 2007
[cited by applicant]
WO 2007033023A2
· 2007
[cited by applicant]
WO 2007109236A2
· 2007
[cited by applicant]
WO 2008008430A2
· 2008
[cited by applicant]
WO 2008036718A2
· 2008
[cited by applicant]
WO 2008095096A2
· 2008
[cited by applicant]
WO 2008095096A9
· 2008
[cited by applicant]
WO 2009012468A2
· 2009
[cited by applicant]
WO 2009036236A1
· 2009
[cited by applicant]
WO 2009036332A2
· 2009
[cited by applicant]
WO 2009049129A1
· 2009
[cited by applicant]
WO 2009075787A1
· 2009
[cited by applicant]
WO 2009126726A1
· 2009
[cited by applicant]
WO 2009147658A2
· 2009
[cited by applicant]
WO 2009154835A2
· 2009
[cited by applicant]
WO 2010006111A2
· 2010
[cited by applicant]
WO 2010023658A2
· 2010
[cited by applicant]
WO 2010065156A1
· 2010
[cited by applicant]
WO 2010115050A2
· 2010
[cited by applicant]
WO 2010127195A2
· 2010
[cited by applicant]
WO 2011002200A2
· 2011
[cited by applicant]
WO 2011014980A1
· 2011
[cited by applicant]
WO 2011024157A1
· 2011
[cited by applicant]
WO 2011108930A1
· 2011
[cited by applicant]
WO 2011128886A1
· 2011
[cited by applicant]
WO 2011146674A2
· 2011
[cited by applicant]
WO 2011157294A1
· 2011
[cited by applicant]
WO 2012009508A2
· 2012
[cited by applicant]
WO 2012009347A2
· 2012
[cited by applicant]
WO 2012082821A2
· 2012
[cited by applicant]
WO 2012092485A1
· 2012
[cited by applicant]
WO 2012093384A1
· 2012
[cited by applicant]
WO 2012096573A1
· 2012
[cited by applicant]
WO 2013048345A1
· 2013
[cited by applicant]
WO 2013056216A1
· 2013
[cited by applicant]
WO 2013158046A1
· 2013
[cited by applicant]
WO 2014030602A1
· 2014
[cited by applicant]
WO 2014100252A1
· 2014
[cited by applicant]
WO 2014186462A1
· 2014
[cited by applicant]
WO 2014201417A1
· 2014
[cited by applicant]
WO 2015013455A2
· 2015
[cited by applicant]
WO 2015127517A1
· 2015
[cited by applicant]
WO 2016059241A2
· 2016
[cited by applicant]
WO 2017091196A1
· 2017
[cited by applicant]
WO 2017207623A1
· 2017
[cited by applicant]
WO 2018085198A1
· 2018
[cited by applicant]
WO 2018129402A1
· 2018
[cited by applicant]
WO 2019245135A1
· 2019
[cited by applicant]
WO 2020061397A1
· 2020
[cited by applicant]
WO 2020102142A1
· 2020
[cited by applicant]
WO 2020154207A1
· 2020
[cited by applicant]
WO 2020186124A1
· 2020
[cited by applicant]
WO 2021097437A1
· 2021
[cited by applicant]
Krutzfeldt et al. (Nucleic Acids Research, 2007, 35, 9, 2885-2892).
[cited by examiner]
Accession No. MI0000291 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000222 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000272 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004543 (1 page) (2018).
[cited by applicant]
Accession No. MIMAT0026476 (1 page) (2018).
[cited by applicant]
Accession No. MI0003186 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0002873 (1 page) (2018).
[cited by applicant]
Accession No. MIMAT0004775 (1 page) (2018).
[cited by applicant]
Accession No. MI0003193 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0002878 (1 page) (2018).
[cited by applicant]
Accession No. MI0000268 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000255 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004557 (1 page) (2018).
[cited by applicant]
Accession No. MI0000737 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0001620 (1 page) (2018).
[cited by applicant]
Accession No. MIMAT000682 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000342 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT00004571 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000318 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004657 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT000617 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000437 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004601 (1 page) (2018).
[cited by applicant]
Accession No. MI0000488 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000732 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000460 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004671 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000060 (3 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000062 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004481 (2 pages) (2018).
[cited by applicant]
NCBI Reference Sequence No. NG_029591.1 (25 pages) (Oct. 21, 2017).
[cited by applicant]
NCBI Reference Sequence No. NM_001243076.2 (5 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NP_001230005.1 (3 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NG_009361.1 (48 pages) (Apr. 13, 2018).
[cited by applicant]
NCBI Reference Sequence No. NM_000633.2 (7 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NP_000624.2 (4 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NM_000657.2 (4 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NP_000648.2 (3 pages) (Oct. 21, 2018).
[cited by applicant]
NCBI Reference Sequence No. NG_028255.1 (14 pages) (Oct. 23, 2018).
[cited by applicant]
NCBI Reference Sequence No. NM_001071.2 (4 pages) (Aug. 21, 2017).
[cited by applicant]
NCBI Reference Sequence No. NP_001062.1 (3 pages) (Oct. 22, 2018).
[cited by applicant]
International Search Report and Written Opinion dated Mar. 5, 2020 received in International Application No. PCT/US19/58706.
[cited by applicant]
International Search Report and Written Opinion dated Feb. 6, 2018 received in International Patent Application No. PCT/US2017/059011.
[cited by applicant]
Invitation to Pay Additional Fees dated Oct. 6, 2021 received in International Application No. PCT/US21/38796.
[cited by applicant]
Invitation to Pay Additional Fees dated Dec. 31, 2019 received in International Application No. PCT/US19/58706.
[cited by applicant]
Extended Supplementary European Search Report dated Sep. 3, 2020 received in European Application No. 17 86 7742.3.
[cited by applicant]
Supplementary Partial European Search Report dated May 29, 2020 received in European Application No. 17 86 7742.3.
[cited by applicant]
Brazilian Search Report dated Sep. 15, 2021 received in Brazilian Application No. BR112019008810-5, together with an English-language translation.
[cited by applicant]
Japanese Notice of Reasons for Rejection dated Jul. 26, 2021 received in Japanese Application No. 2019-523008, together with an English-language translation.
[cited by applicant]
Korean Office Action dated May 10, 2022 received in Korean Patent Application No. 10-2019-7015788, together with an English-language translation.
[cited by applicant]
Japanese Notice of Reasons for Rejection dated Feb. 7, 2022 received in Japanese Application No. 2019-523008, together with an English-language translation.
[cited by applicant]
Acunzo M. et al., “Downregulation of miR-15a and miR-16-1 at 13q14 in Chronic Lymphocytic Leukemia”, Clinical Chemistry 62(4):655-656 (2016).
[cited by applicant]
Altuvia Y. et al., “Clustering and Conservation Patterns of Human microRNAs”, Nucleic Acids Research 33 (8):2697-2706 (2005).
[cited by applicant]
Ambros V., “The Functions of Animal microRNAs”, Nature 431:350-355 (Sep. 16, 2004).
[cited by applicant]
Aqeilan RI et al., “miR-15a and miR-16-1 in Cancer; Discovery, Function and Future Perspectives”, Cell Death and Differentiation 17:215-220 (2010).
[cited by applicant]
Bartel D.P., “MicroRNAs: Target Recognition and Regulatory Functions”, Cell 136(2):215-233 (Jan. 23, 2009).
[cited by applicant]
Bartel DP, “MicroRNAs: Genomics, Biogenesis, Mechanism, and Function”, Cell 116:281-297 (Jan. 23, 2004).
[cited by applicant]
Beaucage S.L. et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotides Synthesis”, Tetrahedron Letters 22(20):1856-1862 (1981).
[cited by applicant]
Carreras C.W. et al., “The Catalytic Mechanism and Structure of Thymidylate Synthase”, Annu. Rev. Biochem. 64:721-762 (1995).
[cited by applicant]
Chen Z. et al., “miR-124 and miR-506 Inhibit Colorectal Cancer Progression by Tareting DNMT3B and DNMT1”, Oncotarget 6(35):38139-38150 (2015).
[cited by applicant]
Chiu Y-L et al., “siRNA Function in RNAi: A Chemical Modification Analysis”, RNA 9(9):1034-1048 (Jan. 1, 2003).
[cited by applicant]
Crose C.M., “Causes and Consequences of microRNA Dysregulation in Cancer”, Nature Reviews Genetics 10:704-714 (Oct. 2009).
[cited by applicant]
Dunham CM et al., “Recombinant RNA Expression”, Nature Methods 4(7):547-548 (Jul. 2007).
[cited by applicant]
Fesler A. et al., “Development of 5-FU Modified Tumor Suppressor miRNAs as a Platform for miRNA Based Cancer Therapeutics”, Abstract 4403, In Proceedings of the American Association for Cancer Research Annual Meeting, A…
[cited by applicant]
Gottesman M.M. et al., “Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters”, Nature Reviews—Cancer 2:48-58 (Jan. 2002).
[cited by applicant]
Iwaizumi M. et al., “DNA Mismatch Repair Proficiency Executing 5-Fluorouracil Cytotoxicity in Colorectal Cancer Cells”, Cancer Biology & Therapy 12(8):756-764 (Oct. 15, 2011).
[cited by applicant]
Karaayvaz M. et al., “miR-129 Promotes Apoptosis and Enhances Chemosensitivity to 5-Fluorouracil in Colorectal Cancer”, Cell Death and Disease 4:e659 (2013).
[cited by applicant]
Kasashima K. et al., “Altered Expression Profiles of MicroRNAs During TPA-Induced Differentiation of HL-60 Cells”, Biochemical and Biophysical Research Communications 322:403-410 (2004).
[cited by applicant]
Lagos-Quintana M. et al., “New microRNAs from Mouse and Human”, RNA 9(2):175-179 (2003).
[cited by applicant]
Lam J KW et al., “siRNA Versus miRNA as Therapeutics for Gene Silencing”, Molecular Therapy-Nucleic Acids 4: e252 (Jan. 1, 2015).
[cited by applicant]
Landgraf P. et al., “A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing”, Cell 129:1401-1414 (Jun. 29, 2007).
[cited by applicant]
Li J. et al., “The Emerging Role of miR-506 in Cancer”, Oncotarget 7(38):62778-62788 (2016).
[cited by applicant]
Li J. et al., “Downregulated miR-506 Expression Facilitates Pancreatic Cancer Progression and Chemoresistance Via SPHK1/Akt/NF-κB Signaling”, Oncogene 35:5501-5514 (2016).
[cited by applicant]
Lui W-O et al., “Patterns of Known and Novel Small RNAs in Human Cervical Cancer”, Cancer Research 67 (13):6031-6043 (Jul. 1, 2007).
[cited by applicant]
Maitra A. et al., “Pancreatic Cancer”, Annual Review of Pathology: Mechanisms of Disease 3:157-188 (2008).
[cited by applicant]
Matteucci M.D. et al., “Synthesis of Deoxyoligonucleotides on a Polymer Support”, J. Am. Chem. Soc. 103:3185-3191 (1981).
[cited by applicant]
Oettle H. et al., “Adjuvant Chemotherapy With Gemcitabine and Long-Term Outcomes Among Patients With Resected Pancreatic Cancer”, JAMA 310(14):1473-1481 (Oct. 9, 2013).
[cited by applicant]
Peng F. et al., “Direct Targeting of SUZ12/ROCK2 by miR-200b/c Inhibits Cholangiocarcinoma Tumourigenesis and Metastasis”, British Journal of Cancer 109:3092-3104 (2013).
[cited by applicant]
Pettersen H.S. et al., “UNG-Initiated Base Excision Repair is the Major Repair Route for 5-Fluorouracil in DAN, But 5-Fluorouracil Cytotoxicity Depends Mainly on RNA Incorporation”, Nucleic Acids Research 39(19):8430-84…
[cited by applicant]
Scaringe S.A. et al., “Novel RNA Synthesis Method Using 5′-O-Silyl-2′-O-Orthoester Protecting Groups”, J. Am. Chem. Soc. 120(45):11820-11821 (1998).
[cited by applicant]
Siegel R.L. et al., “Cancer Statistics”, Cancer J. Clin. 65(1):5-29 (Jan./Feb. 2015).
[cited by applicant]
Song B. et al., “Molecular Mechanism of Chemoresistance by miR-215 in Osteosarcoma and Colon Cancer Cells”, Molecular Cancer 9(96):1476-1498 (2010).
[cited by applicant]
Song B. et al., “miR-192 Regulates Dihydrofolate Reductase and Cellular Proliferation Through the p53-microRNA Circuit”, Clin. Cancer Res. 14(24):8080-8086 (Dec. 15, 2008).
[cited by applicant]
Watts J.K. et al., “Chemically Modified siRNA: Tools and Applications”, Drug Discovery Today 13(19/20):842-855 (Oct. 1, 2008).
[cited by applicant]
Wu N. et al., “Development of Novel miR-129 Mimics With Enhanced Efficacy to Eliminate Chemoresistant Colon Cancer Stem Cells”, Oncotarget 9(10):8887-8897 (2018).
[cited by applicant]
Wu S-Y et al., “Development of Modified siRNA Molecules Incorporating 5-Fluoro-2-Deoxyuridine Residues to Enhance Cytotoxicity”, Nucleic Acids Research 41(8):4650-4659 (Apr. 1, 2013).
[cited by applicant]
Wu J. et al., “miR-129 Regulates Cell Proliferation by Downregulating Cdk6 Expression”, Cell Cycle 9(9):1809-1818 (May 1, 2010).
[cited by applicant]
Yu X. et al., “Growth Inhibitory Effects of Three miR-129 Family Members on Gastric Cancer”, Gene 535:87-93 (2013).
[cited by applicant]
Zhai H. et al., “Inhibition of Colorectal Cancer Stem Cell Survival and Invasive Potential by Has-miR-140-5p Mediated Suppression of Smad2 and Autophagy”, Oncotarget 6(23):19735-19746 (2015).
[cited by applicant]
Zhai H. et al., “Inhibition of Autophagy and Tumor Growth in Colon Cancer by miR-502”, Oncogene 32 (12):1570-1579 (2013).
[cited by applicant]
Accession No. MIMAT0000431 (2 pages) (2018).
[cited by applicant]
NCBI Reference Sequence No. NT_010498.16 (6 pages) (Mar. 26, 2018).
[cited by applicant]
Accession No. MIMAT0004597 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000252 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0000242 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004548 (1 page) (2018).
[cited by applicant]
Accession No. MI0000069 (3 pages) (2018).
[cited by applicant]
Accession No. MI0000068 (2 pages) (2018).
[cited by applicant]
Accession No. MIMAT0004488 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000456 (2 pages) (2018).
[cited by applicant]
Accession No. MI0000234 (2 pages) (2018).
[cited by applicant]
Chinese Office Action dated Jun. 1, 2022 received in Chinese Patent Application No. 201780081456.7, together with an English-language translation.
[cited by applicant]
Mexican Office Action dated Mar. 29, 2022 received in Mexican Application No. MX/a/2019/005101, together with an English-language translation.
[cited by applicant]
Chinese Office Action dated Jun. 16, 2023 received in Chinese Patent Application No. 201780081456.7, 18 pages.
[cited by applicant]
Partial Supplementary European Search Report dated Jul. 11, 2023 received in European Patent Application No. 19878184.1, 11 pages.
[cited by applicant]
Peacock, H., et al., “Chemical Modification of siRNA Bases to Probe and Enhance RNA Interference”, J Org Chem., Sep. 16, 2011, pp. 7295-7300, 76(18).
[cited by applicant]
Notice of Reasons for Rejection dated Aug. 4, 2023 received in Japanese Patent Application No. 2022-133279, 11 pages.
[cited by applicant]
Chinese Office Action dated Jan. 7, 2024 received in Chinese Patent Application No. 201980087509.5, 22 pages.
[cited by applicant]
Second Office Action received in CN 201980087509.5 dated Oct. 1, 2024, 27 pages.
[cited by applicant]
Third Office Action received in CN Patent Application No. 201980087509.5 dated Feb. 15, 2025, 137 pages.
[cited by applicant]
Decision of Rejection received in KR Patent Application No. 10-2021-7016590 dated Feb. 19, 2025, 10 pages.
[cited by applicant]